

# ISPOR 2022

The Leading Global Conference for Health Economics and Outcomes Research

May 15-18  
Gaylord National Resort and  
Convention Center  
Washington, DC, USA Area



## PROGRAM

---

*The Future of HEOR  
in Patient-Driven Digital  
Healthcare Systems*



 #ISPORAnnual  
[www.ispor.org](http://www.ispor.org)

# Conference Program

## Monday May 16

6:30AM-5:30PM **Registration**  
*Maryland Ballroom Pre-function*

7:15AM-8:15AM **Educational Symposium** *Maryland C*  
●●● 100: **Can Value-Based Care Exist Without Value-Based Research** *Sponsor: Cardinal Health*

8:30AM-9:45AM **Welcome and Plenary Session 1**  
*Maryland B*  
●●● 101: **HTA on the Run**

9:45AM-10:15AM **Break** *Prince George's Exhibition Hall A-C*

9:45AM-1:15PM **Poster Session 1**  
*(Presentation Time: 12:15PM-1:15PM)*  
●● Prince George's Exhibition Hall A-C

9:45AM-7:00PM **Poster Viewing & Exhibit Hall Open**  
●● Prince George's Exhibition Hall A-C

### 10:15AM-11:15AM Breakout Sessions

- 102: Health Technology Assessment of Treatments and Diagnostics for COVID-19: Best-Practice Guidance *Virtual*
- 103: How to Apply Machine Learning to Health Economics and Outcomes Research: Findings From the ISPOR Machine Learning Task Force *National Harbor 10-11*
- 104: No Label, No Interest: How Should Sponsors Integrate Patient Experience Data Not Intended for Labeling in New Drug Applications? *National Harbor 12-13*
- 105: SEE Sense: Tools for Conducting Structured Expert Elicitation to Support Healthcare Decision Making *Virtual*
- 106: Systematic Approaches to Assessing Physician Decision-Making Practices and Treatment Preferences *Virtual*
- 107: What Is the Preferred Approach to US Drug Pricing Reforms: International Reference Pricing or Value-Based Pricing? *Maryland C*

### Podiums

- 108: Development and Methods for Quality-of-Life, Health Utilities and Patient-Centered Measures *Virtual*
- 109: Qualitative and Quantitative Evidence on Patient-Caregiver Dyad *Chesapeake D-F*
- 110: Tackling Reimbursement Challenges to Fair Access to Medicine *HEOR Theater, Prince George's Exhibition Hall A-C*

10:15AM-11:30AM **Signal Series** *Maryland A*

●●● 111: **New Analytical Approaches to 21st Century Challenges**

11:15AM-1:15PM **Lunch** *Prince George's Exhibition Hall A-C*

11:45AM-12:45PM **Educational Symposium** *Maryland C*

●●● 112: **Advances in the Development and Application of Real-World Evidence: Learnings from the US and China**  
*Sponsor: Analysis Group*

11:45AM-12:45PM **Discussion Groups** *Discussion Lounge, Prince George's Exhibition Hall A-C*

● 113: Machine Learning Discussion Group

### 11:45AM-12:45PM Forums

- 114: High-Cost Drugs: Experiences and Barriers to Access in Latin America *National Harbor 12-13*
- 115: Measuring Health Preferences of Multiple Stakeholders: Issues and Challenges *Chesapeake D-F*
- 116: Open Source in Precision Medicine: The Perfect Fit? *National Harbor 10-11*

### 12:15PM-1:15PM Poster Tours

- 117: Cardiovascular Disease Tour *Poster Tour Area A, Prince George's Exhibition Hall A-C*
- 118: Real-World Evidence Tour *Poster Tour Area B, Prince George's Exhibition Hall A-C*

12:45PM-1:15PM **HEOR Theater** *HEOR Theater, Prince George's Exhibition Hall A-C*

●● 119: **Real-World Data for Comparative Effectiveness Research** *Sponsor: OM1*

### 1:30PM-2:30PM Breakout Sessions

- 120: Challenges in Value Assessment of Technologies for COVID-19: A Health Economics Perspective *National Harbor 10-11*
- 121: Dealing With Disability in Health Technology Assessment (HTA) *Virtual*
- 122: Defining and Operationalizing No-Value Care *Virtual*
- 123: How Can a Robust Real-World Data Infrastructure Advance a More Patient-Centered Approach to Drug Development? *Maryland C*
- 124: Let Them in or Build a Wall? Transporting Inferences Across Borders *National Harbor 12-13*
- 125: Multi-Stakeholder Survey on Use of Digital Health Tools Transforming the Process for Development and Use of Medical Device Technologies *Virtual*
- 126: Optimizing the Use of Patient-Reported Outcomes in Clinical Trials to Inform Decision Making: The PROTEUS Consortium *Chesapeake D-F*

**Podiums**

- 128: Emerging Methods in Economic Evaluations *Virtual*
- 129: Evidence on Treatment Access, Disparities and Social Determinants of Health *HEOR Theater, Prince George's Exhibition Hall A-C*

**1:30PM-2:30PM Spotlight Session Maryland A**

- 130: **Improving the Acceptability of RWE: What's New in 2022?**

**2:30PM-3:00PM Break Prince George's Exhibition Hall A-C**

**3:00PM-4:00PM Discussion Groups Discussion Lounge, Prince George's Exhibition Hall A-C**

- 131: **Value Assessment of Technologies Discussion Group**

**3:00PM-4:00PM Educational Symposium Maryland C**

- 132: **Digging Deeper - Uncovering Expanded Patient Insights through Linked Data** *Sponsor: CorEvitas*

**3:00PM-4:00PM Forums**

- 133: Building Diversity in the HEOR Workforce: A Call for Input and Action *National Harbor 12-13*
- 134: Making the Case for PGHD: Proving that Collection and Application of Patient-Generated Health Data Can Be Rigorous and Vital to Improving HTA *Chesapeake D-F*
- 135: Performance Outcome Assessment Emerging Good Practices Task Force: Final Recommendations *National Harbor 10-11*

**3:00PM-6:30PM Poster Session 2**

*(Presentation Time: 5:30PM-6:30PM)*

- Prince George's Exhibition Hall A-C

**3:45PM-4:15PM HEOR Theater HEOR Theater, Prince George's Exhibition Hall A-C**

- 136: **Utilizing RWE and HEOR Throughout the Product Lifecycle: From Product Positioning to Market Access and Reimbursement** *Sponsor: Lumen Value & Access*

**4:30PM-5:30PM Breakout Sessions**

- 137: Artificial Intelligence in HEOR: A Student Roundtable Panel *Virtual*
- 138: How Much Weight Should be Placed on Additional Value Elements in Health Technology Assessment? *Maryland A*
- 139: In or Out? Challenges and Opportunities to the Collection of Patient Preference Information Within Clinical Trials *Maryland C*
- 140: Is Open-Source Model Development Sustainable? *Virtual*
- 141: Making Your Key Messages Heard and Understood: Strategies and Methods for Effective Communication of Scientific Information to Non-Technical Audiences *Chesapeake D-F*

- 142: Measuring Health Equity: Lessons from an Integrated Healthcare System *National Harbor 12-13*

- 143: Using Real-World Data to Provide Insights in the COVID-19 Crisis: Challenges and Opportunities *National Harbor 10-11*

**Podiums**

- 144: Emerging Evidence on SARS-COV2 Vaccine Utilization and Outcomes *HEOR Theater, Prince George's Exhibition Hall A-C*
- 145: HEOR Studies in Alzheimer's Disease and Related Dementias *Virtual*

**5:30PM-6:30PM Poster Tours**

- 146: Diabetes/Endocrine/Metabolic Disorders Tour *Poster Tour Area A, Prince George's Exhibition Hall A-C*
- 147: LMIC Focused Work Tour *Poster Tour Area B, Prince George's Exhibition Hall A-C*

**5:30PM-7:00PM Welcome Reception**

*Prince George's Exhibition Hall A-C*

**Tuesday May 17**

**7:30AM-5:30PM Registration Maryland Ballroom Pre-function**

**8:30AM-9:45AM Plenary Session 2 Maryland B**

- 200: **Can Big Data Analytics Deliver on the Promises of Personalized Medicine for All? Unpacking the Health Equity Considerations**

**9:45AM-10:15AM Break Prince George's Exhibition Hall A-C**

**9:45AM-1:15PM Poster Session 3**

*(Presentation Time: 12:15PM-1:15PM)*

- Prince George's Exhibition Hall A-C

**9:45AM-7:00PM Poster Viewing & Exhibit Hall Open**

- Prince George's Exhibition Hall A-C

**10:15AM-11:15AM Breakout Sessions**

- 201: Applying Advanced Real-World Evidence to HEOR: What, Why, and How? *National Harbor 12-13*
- 202: Are We Patient and Care-Partner Centric Enough in Early Alzheimer's Disease Clinical Trials? The Potential Limitations of Using Legacy Clinical Outcome Assessments (COA) in the New Era of Alzheimer's Disease Drug Development *Virtual*
- 203: Conceptual Issues in the Valuation of Health in Children *Virtual*
- 204: Could Gene Therapy Value-Based Purchasing Become Common Thanks to the New CMS Rule on Medicaid Best Price? *National Harbor 10-11*

●● 205: Engaging Black Americans in Outcomes Research Studies Amidst a Challenging COVID Operating Environment: Experience From an Ongoing Vaccine Hesitancy Study in Philadelphia *Chesapeake D-F*

●●● 206: Lessons Learned From Health Technology Assessment Pilot Projects to Assess Real-World Evidence's Usefulness in Reassessments of Effectiveness and Value *Maryland C*

●● 207: Severity Shortfall: Graceful or Awkward? Contextual or Continuous? *Virtual*

**Podium**

●● 208: Machine Learning in HEOR *HEOR Theater, Prince George's Exhibition Hall A-C*

10:15AM-11:30AM **Spotlight Session** *Maryland A*

●●● 209: **Emerging Methods in Real-World Analyses Involving Social Determinants of Health**

11:15AM-1:15PM **Lunch** *Prince George's Exhibition Hall A-C*

11:45AM-12:45PM **Discussion Groups** *Discussion Lounge, Prince George's Exhibition Hall A-C*

● 210: Health Technology Assessment Discussion Group

11:45AM-12:45PM **Educational Symposium** *Maryland C*

●●● 211: **Can Pharmaceutical Pricing Move Beyond Cost/QALY for Value Consideration?** *Sponsor: Novartis Gene Therapies*

11:45AM-12:45PM **Forums**

● 212: ISPOR Task Force on Emerging Good Practice in Quantitative Benefit-Risk Assessment: Final Recommendations *National Harbor 12-13*

● 213: Nutrition Economics – Are We Ready for A New Approach? Opportunities To Advance the Science *Chesapeake D-F*

● 214: The Evolution of Biosimilar Markets: Key Elements for Long-Term Sustainability of the Healthcare Ecosystem *National Harbor 10-11*

12:15PM-1:15PM **Poster Tours**

● 215: Student Research Spotlight Tour *Tour Area A, Prince George's Exhibition Hall A-C*

● 216: Infectious Disease (Non-Vaccine) Tour *Poster Tour Area B, Prince George's Exhibition Hall A-C*

12:45PM-1:15PM **HEOR Theater** *HEOR Theater, Prince George's Exhibition Hall A-C*

●● 217: **Comparing Registry and Electronic Health Record (EHR) Data for Real-World Evidence Generation: Heart Failure as a Case Study** *Sponsor: Veradigm*

1:30PM-2:30PM **Breakout Sessions**

●● 219: Best Practices for Causal Study Designs Using Real-World Data *National Harbor 10-11*

●● 220: Do We Really Need Another Preference Study? Using Benefit-Transfer Methods to Increase Use of Patient-Preference Data in Decision Making *Chesapeake D-F*

●● 221: Paying for Digital Therapeutics (DTx): What Evidence Is Needed? *National Harbor 12-13*

●●● 222: Standing Up Computable Phenotypes for Generating Real-World Evidence: What Are Computable Phenotypes and Can They Really Be Standardized and Reused? *Maryland C*

●● 223: Surrogate Endpoints Under Attack: Is It Still Worth Performing Surrogacy Validation? Lessons from NSCLC *HEOR Theater, Prince George's Exhibition Hall A-C*

●● 224: Technology and Machine-Learning Enabled Systematic Reviews: How Can They Be Leveraged to Support Global Health Technology Assessments? *Virtual*

●●● 225: The Empowered Patient: Driving Individual and Population Health with Data & Technology *Maryland A*

●● 226: What Statistics and Analytics Resources Are Available to HEOR Professionals? *Virtual*

**Podium**

●● 227: Addressing the Impact of Social Determinants and Disparities on Health Outcomes *Virtual*

2:30PM-3:00PM **Break** *Prince George's Exhibition Hall A-C*

3:00PM-4:00PM **Discussion Groups** *Discussion Lounge, Prince George's Exhibition Hall A-C*

● 229: Health Equity Discussion Group

3:00PM-4:00PM **Educational Symposium** *Maryland C*

●●● 230: **Downstream Effects of Pandemic-Related Disruptions in Healthcare Utilization and Cost: Insights from Healthcare Claims and Survey Data** *Sponsor: IBM Watson Health*

3:00PM-4:00PM **Forums**

● 231: Collaboration on HTA Within the EU: What Does It Mean for CEE Countries? *Chesapeake D-F*

● 232: How Can We Make the Study of Patient Preferences More Useful to Decision-Makers in Health? The Final Recommendations from the ISPOR Using Patient Preferences to Inform Decision Making Good Practices Task Force *National Harbor 12-13*

3:00PM-4:00PM **New Professionals Session** *National Harbor 10-11*

● 233: Things They Didn't Teach in Grad School: Survival Skills for New Professionals

3:00PM-6:30PM **Poster Session 4**

*(Presentation Time: 5:30PM-6:30PM)*

●● *Prince George's Exhibition Hall A-C*

3:45PM-4:15PM **HEOR Theater** *HEOR Theater, Prince George's Exhibition Hall A-C*

●● 234: **Transforming Real-World Data Into Insights That Drive Value** *Sponsor: Evidera, a PPD business*

**4:30PM-5:30PM Breakout Sessions**

- 235: Combining Real-World and Clinical Trial Data to Study the Effectiveness of Thrombolytics for Treating Patients with COVID-19 Associated Acute Respiratory Distress Syndrome *Maryland C*
- 236: Getting Real With Real-World Evidence for Regulatory Decision Making: Where Are We Going? *National Harbor 12-13*
- 237: High Quality of Life Against All Odds? Evaluating Quality of Life Measurement Approaches in Degenerative Diseases Affecting Children and Young Adults *Maryland A*
- 238: How Can HTA Become Truly Participatory? Implementing the Guidance of the Joint HTAi – ISPOR Task Force Deliberative Processes for HTA *National Harbor 10-11*
- 239: National Institutes of Health Small Business and Commercialization Grants: You Too Can Access Funding *Chesapeake D-F*
- 240: The Challenges of Bringing Cell & Gene Therapies to Emerging Markets *Virtual*
- 241: Women in HEOR Session: Strengthening Communication Practices *HEOR Theater, Prince George's Exhibition Hall A-C*

**Podiums**

- 242: Clinical Trial Methods and Applications in HEOR *Virtual*
- 243: Economic Evaluation of Disease Burden Using Real-World Data *Virtual*

**5:30PM-6:30PM Poster Tours**

- 244: Rare and Orphan Diseases Tour *Poster Tour Area A, Prince George's Exhibition Hall A-C*
- 245: Oncology Tour *Poster Tour Area B, Prince George's Exhibition Hall A-C*

**5:30PM-7:00PM Networking Social** *Prince George's Exhibition Hall A-C*

**Wednesday May 18**

**7:30AM-1:00PM Registration**  
*Maryland Ballroom Pre-function*

**8:00AM-9:00AM Breakout Sessions**

- 300: Approaches for Utilizing Patient Preference Information to Inform Clinical Trial Design *Virtual*
- 301: Assessing Real Option Value in Health Technology Assessment of Drugs *Chesapeake D-F*
- 302: Health Technology Assessment for Gene Therapies: Are Our Methods Fit for Purpose? *Virtual*
- 303: How Best to Frame Cost-Effectiveness Thresholds for Policy Making in the US *Maryland A*

●●● 304: Is the Global Real-World Data (RWD) Supply-Chain Broken? Choosing between RWD Quality Versus Locality in Supporting Single Arm Submissions *Maryland C*

●● 305: The Role of Actuarial Science in US Manufacturers' Potential Budget Impact and Cost-Effectiveness Value Propositions *National Harbor 12-13*

●● 306: What Is Value? How Can We Appropriately Assess the Value of Digital Health Technologies *National Harbor 10-11*

**9:00AM-10:00AM Poster Tours**

- 307: Vaccines Tour *Poster Tour Area A, Prince George's Exhibition Hall A-C*
- 308: Mental Health Tour *Poster Tour Area B, Prince George's Exhibition Hall A-C*

**9:00AM-10:00AM Coffee Break** *Prince George's Exhibition Hall A-C*

**9:00AM-12:45PM Poster Session 5**

*(Presentation Time: 9:00AM-10:00AM)*  
●● Prince George's Exhibition Hall A-C

**9:00AM-12:45PM Poster Viewing & Exhibit Hall Open**

●● Prince George's Exhibition Hall A-C

**10:00AM-11:00AM Breakout Sessions**

- 309: Advancing Research on Emotional Well-Being: Introducing a Family Well-Being Research Network *Virtual*
- 310: Are We Capturing the Multidimensional Value of Therapies for Rare Diseases Through the QALY? *National Harbor 12-13*

●●● 311: Engage for What? Rethinking the Purpose of Stakeholder Engagement in Healthcare Research and Health Technology Assessment (HTA) *Maryland C*

●● 312: HTA in a Public Crisis: Communication Challenges *Virtual*

●● 313: Relevance of Using International Real-World Data in Regulatory and HTA Decision Making *Chesapeake D-F*

●● 314: The Role of Real-World Evidence in Regulatory Evaluation of Medical Devices: A Global Review *National Harbor 10-11*

**Podium**

●● 315: Studies on COVID-19 Healthcare Impacts *HEOR Theater, Prince George's Exhibition Hall A-C*

**10:00AM-11:00AM Spotlight Session** *Maryland A*

●●● 316: Trial Emulation with RWD—Evidence on Feasibility, Challenges, and Opportunities


**11:30AM-12:45PM Plenary Session 3** *Maryland B*

●●● 317: **The Patient (Finally) at the Center: How Can We Leverage Digital Data to Make Patient-Focused Adoption, Reimbursement, and Management Decisions?**

# Poster and Exhibit Hall Floor Plan

## Exhibits and Poster Viewing Hours (Exhibit Hall)

Monday, May 16: 9:45AM-7:00PM | Tuesday, May 17: 9:45AM-7:00PM | Wednesday, May 18: 9:00AM-12:45PM



## Exhibitor listing and location (As of April 21, 2022)

Adelphi Real World	114	Evidera *	414	OncoHealth	522
Aetion	714	Fiecon	506	Ontada	217
Alira Health	406	Genesis Research	106	OPEN Health *	400
Allelica Inc.	622	Health Analytics	708	Optum	300
AmerisourceBergen/Xcenda	100	HealthCore, Inc. *	500	PAI Policy Analysis Inc	306
Amplify Health	424	IBM Watson Health *	214	Panalgo	510
Arcadia	523	ICON	Virtual Exhibitor	Partnership for Health Analytic Research	410
Barrington James	625	IHME Client Services	524	PicnicHealth	301
Biofourmis	723	IQVIA	514	PRMA Consulting	405
Blue Health Intelligence	423	ISPOR	314	Rare Patient Voice	303
Boston Strategic Partners, Inc.	623	Lumina	600	RTI Health Solutions	322
Cardinal Health *	606	Lumen Value & Access	202	SAS Institute Inc.	421
Carevive Systems Inc.	624	Mapi Research Trust	525	Syapse Inc.	206
Cerner Enviza	222	Marksman Healthcare Communications	618	Traverse Therapeutics	200
Certara	720	MDClone Inc.	118	Veradigm	120
CorEvitas LLC	610	National Pharmaceutical Council	221	Verantos	122
Curta, Inc.	614	OM1 *	310	Workpartners – Better Health Worldwide, Inc.	219
Cytel	725	OMNY	719		
DistillerSR	422				

\*Indicates Sponsor/Symposia host